Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

A Phase 2 Study of ABI-009 in Patients With Advanced Malignant PEComa

Complete title: A phase 2 multi-center investigation of efficacy of ABI-009 (nab-rapamycin) in patients with advanced malignant perivascular epithelioid cell tumors (PEComa)

Research Study Number 20151429
 
Principal Investigator Lee Cranmer
 
Phase II

Research Study Description

A phase 2 multi-center investigation of efficacy of ABI-009 (nab-rapamycin) in patients with advanced malignant perivascular epithelioid cell tumor (PEComa)

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number 20151429
 
Contact Seattle Cancer Care Alliance Intake Office
 
Telephone 800-804-8824 / 206-606-1024
 

Keywords: Solid Tumors; Neoplasms; Neoplasms, Connective and Soft Tissue; Perivascular Epithelioid Cell Neoplasms (PEComa)

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials